This also highlights a potential heterogeneity in PD-L1 scoring methodologies across studies, in terms of evaluation methodology, such as the analysis of biopsies that do not always reflect the molecular status of the entire tumor, and suggests that alternative PD-L1 thresholds or evaluation methods may be needed to optimize patient selection. The gene discussed is CD274; the disease is neoplasm.